Early study backs Pharmacyclics' MRI (magnetic resonance imaging) agent:
This article was originally published in Clinica
Pharmacyclics has presented additional data supporting the use of its texaphyrin MRI-based agent for detecting vulnerable atherosclerotic plaque. Preclinical data, presented at this month's Society for Cardiac Magnetic Resonance in San Francisco, showed the gadolinium-based texaphyrin compound localised in plaque and enhanced MRI signal in atherosclerotic animal models. The Sunnyvale, California firm is currently developing Antrin, a texaphyrin-based, light-activated product for treating peripheral arterial disease and coronary artery disease.